for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Knight Therapeutics Inc

GUD.TO

Latest Trade

7.62CAD

Change

-0.06(-0.78%)

Volume

116,804

Today's Range

7.59

 - 

7.73

52 Week Range

7.10

 - 

8.88

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
7.68
Open
7.72
Volume
116,804
3M AVG Volume
5.93
Today's High
7.73
Today's Low
7.59
52 Week High
8.88
52 Week Low
7.10
Shares Out (MIL)
135.63
Market Cap (MIL)
1,033.49
Forward P/E
43.46
Dividend (Yield %)
--

Latest Developments

More

Knight Therapeutics Inc Says Co, Medison Biotech (1995) Ltd Have Agreed To Separate Their Businesses

Knight Therapeutics Inc- QTRLY Revenue C$4 Million Versus C$ 3.2 Million

Brazil's Biotoscana Appoints Claudio Coracini As Interim CEO After Agreement To Sell Control To Knight Therapeutics- Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Knight Therapeutics Inc

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.

Industry

Biotechnology & Drugs

Contact Info

3400 De Maisonneuve Blvd W

+1.514.4844483

https://www.gud-knight.com/

Executive Leadership

James C. Gale

Independent Chairman of the Board

Samira Sakhia

President, Chief Financial Officer, Director

Jonathan Ross Goodman

Chief Executive Officer, Director

Amal Khouri

Vice President - Business Development

Jody Engel

Director - Business Development

Key Stats

1.86 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, CAD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (CAD)

2016

0.150

2017

0.120

2018

0.170

2019(E)

0.184
Price To Earnings (TTM)
51.26
Price To Sales (TTM)
73.41
Price To Book (MRQ)
1.08
Price To Cash Flow (TTM)
44.00
Total Debt To Equity (MRQ)
0.10
LT Debt To Equity (MRQ)
0.07
Return on Investment (TTM)
2.15
Return on Equity (TTM)
2.07

Latest News

Latest News

Canada's Knight Therapeutics to acquire Biotoscana control by Nov 29-filing

Canada's Knight Therapeutics Inc and shareholders of Biotoscana Investments expect to conclude transfer of control of the Latin American pharmaceutical company by Nov. 29, the latter said in a securities filing on Monday.

Knight Therapeutics to purchase Biotoscana in $281 million deal

Knight Therapeutics <GUD.TO> will buy Brazilian pharmaceutical company Biotoscana Investments <GBIO33.SA> in a deal valued at 1.16 billion reais ($281 million) that will create a pharmaceutical platform in fast growing markets in Latin America.

Shares in Biotoscana, Knight Therapeutics up after deal announcement

Shares in Canada's Knight Therapeutics were up 9% in Toronto after the announcement of acquisition of Latin American pharmaceutical company Biotoscana Investments earlier on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up